

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	1	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	1.	AGUAYO, Alvaro and PATT, Yehuda Z., "Liver Cancer," Clinics in Liver Disease Vol 5(2):479-507 (2001)	
	2.	AGUAYO, Alvaro and PATT, Yehuda Z., "Liver Tumors: Nonsurgical Treatment of Hepatocellular Carcinoma," Clinics in Liver Disease Vol 5 (1):175-189 (2001)	
	3.	ARASE, Yasuji et al., "The Long Term Efficacy of Glycyrrhizin in Chronic Hepatitis C Patients," Cancer Vol. 79 (8): 1494-1500 (1997)	
	4.	BARNETT, JR., Carlton C. and CURLEY, Steven A., "Ablative Techniques for Hepatocellular Carcinoma," Seminars in Oncology Vol 28(5):487-496 (2001)	
	5.	CARR, Brian I. et al., K Vitamins, PTP Antagonism, and Cell Growth Arrest," J. Cell. Physiol. 193:263-274 (2002)	
	6.	CORSI, M.M. et al., "The Therapeutic Potential of Aloe Vera in Tumor-Bearing Rats," Tissue Reactions XX(4):115-118 (1998)	
	7.	DRAGNEV, Konstantin H. et al., "The Retinoids and Cancer Prevention Mechanisms," The Oncologist 5:361-368 (2000)	
	8.	FENECH, M., "Micronutrients and genomic stability: a new paradigm for recommended dietary allowances (RDAs)," Food and Chemical Toxicology 40:1113-	

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	2	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		1117 (2002)	
	9.	FENECH, Michael, "Recommended dietary allowances (RDAs) for genomic stability," Mutation Research 480-481:51-54 (2001)	
	10.	GEORGIADES, Christos S. et al., "New Nonsurgical Therapies in the Treatment of Hepatocellular Carcinoma," Techniques in Vascular and Interventional Radiology 4(3):193-199 (2001)	
	11.	GIOVANNINI, M. et al., "Hepatocellular carcinoma," Br. J. Cancer 84(Suppl.2):74-77 (2001)	
	12.	HE, Youping et al., Effects of Carotenoid-Rich Food Extracts on the Development of Preneoplastic Lesions in Rat Liver and on In Vivo and In Vitro Antioxidant Status," Nutrition and Cancer 27(3):238-244 (1997)	
	13.	KANG, Jiu-Hong et al., "Effects of ascorbic acid and DL- α -tocopherol on humanhepatoma cell proliferation and redifferentiation," Acta Pharmacol. Sin. 21(4):348-352 (2000)	
	14.	KANG, Jiu-Hong et al., "Effects of ascorbic acid on human hepatoma cell proliferation and redifferentiation," Acta Pharmacol. Sin. 20(11):1019-1024 (1999)	
	15.	KASHEF, Elika and ROBERTS, John P., "Transplantation for Hepatocellular	

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	3	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Carcinoma," Seminars in Oncology 28(5):497-502 (2001)	
	16.	KEW, M.C., "Hepatitis viruses and hepatocellular carcinoma," Res. Virol. 149:257-262 (1998)	
	17.	KUO, Po-Lin et al., "The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines," Life Sciences 71:1879-1892 (2002)	
	18.	KUYVENHOVEN, J. Ph. Et al., "Practical Management of Hepatocellular Carcinoma," Scand. J. Gastroenterol. Suppl 234:82-87 (2001)	
	19.	LEE, Simon Ming Yuen et al., "Paeoniae Radix, a Chinese herbal extract, inhibit hepatoma cells growth by inducing apoptosis in a p53 independent pathway," Life Sciences 72:2267-2277 (2002)	
	20.	LEE, Kwang Youl et al., "Aloesin up-regulates cyclin E/CDK2 kinase activity via inducing the protein levels of cyclin E, CDK2, and CDC25A in SK-HEP-1 cells," Biochem. and Mol. Biol. International 41(2):285-292 (1997)	
	21.	LEUNG, Thomas W.T. and JOHNSON, Philip J., "Systemic Therapy for Hepatocellular Carcinoma," Seminars in Oncology 28(5):514-520 (2001)	
	22.	LITTLE, Sarah A. and FONG, Yuman, "Hepatocellular Carcinoma: Current Surgical	

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	4	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
		Management," Seminars in Oncology 28(5):474-486 (2001)		
	23.	MEYSKENS, Frank L. et al., "Phase II trial of oral β -all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)," Investigational New Drugs 16:171-173 (1998)		
	24.	MORADPOUR, Darius et al, "Hepatitis C: an update," Swiss Med. Wkly. 131:291-298 (2001)		
	25.	MORADPOUR, D. et al., Hepatitis C: A concise review," Minerva Med. 92:329-339 (2001)		
	26.	MORIWAKI, Hisataka et al., "Nutritional pharmacotherapy of chronic liver disease: from support of liver failure to prevention of liver cancer," J. Gastroenterol. 35(Suppl XII):13-17 (2000)		
	27.	MUTO, Yasutoshi et al., "Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma," New England J. of Med. 334(24):1561-1567 (1996)		
	28.	NACCARATO, R. and FARINATI, F., "Hepatocellular Carcinoma, Alcohol, and Cirrhosis: Facts and Hypotheses," Digestive Diseases and Sciences 36(8):1137-1142 (1991)		

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-736-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	5	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	29.	NAKAMURA, Noriaki et al., "Apoptosis in Human Hepatoma Cell Line Induced by 4,5-Didehydrogeranylgeranoic Acid (Acyclic Retinoid) via Down-Regulation of Transforming Growth Factor- α " Biochem. and Biophys. Res. Comm. 219:100-104 (1996)	
	30.	NI, Runshou et al., "Cell Growth Inhibition by a Novel Vitamin K Is Associated with Induction of Protein Tyrosine Phosphorylation," J. of Biol. Chem. 273(16):9906-9911 (1998)	
	31.	NISHIKAWA, Yuji et al., "Inhibition of Hepatoma Cell Growth in Vitro by Arylating and Non-arylating K Vitamin Analogs," J. of Biol. Chem. 274(49):34803-34810 (1999)	
	32.	NISHIKAWA, Yuji et al., "Growth Inhibition of Hepatoma Cells Induced by Vitamin K and Its Analogs," J. of Biol. Chem. 270(47):28304-28310 (1995)	
	33.	OKUNO, Masataka et al., "Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives," J. Gastroenterol. And Hepatol. 16:1329-1335 (2001)	
	34.	PUATANACHOKCHAI, Rawiwan et al., "Inhibitory effects of lemon grass (Cymbopogon citratus, Stapf) extract on the early phase of hepatocarcinogenesis after initiation with diethylnitrosamine in male Fischer 344 rats," Cancer Letters 183:9-15 (2002)	
	35.	RIEDER, A. et al., "Delay of Diethylnitrosamine-Induced Hepatoma in Rats by Carrot	

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	6	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Feeding," Oncology 40:120-123 (1983)	
	36.	ROSS, Ronald K. et al., "Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma," The Lancet 339 (8799):943-946 (1992)	
	37.	SAKAGAMI, Hiroshi et al., Apoptosis-Inducing Activity of Vitamin C and Vitamin K," Cellular and Molecular Biol. 46(1):129-143 (2000)	
	38.	SAKAIDA, Isao et al., "Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet," J of Hepatology 28:298-306 (1998)	
	39.	SEITZ, Helmut et al., "Alcohol and Cancer," Recent Developments in Alcoholism 14: The Consequences of Alcoholism, edited by Galanter, Plenum Press U.S.A., pp. 67-95 (1998)	
	40.	SHAMAAN, Nor Aripin et al., "Vitamin C and Aloe Vera Supplementation Protects from Chemical Hepatocarcinogenesis in the Rat," Nutrition 14 (11/12): 846-852 (1998)	
	41.	SHIMIZU, Satoshi et al., "Liver and Biliary, High prevalence of antibody to hepatitis C virus in heavy drinkers with chronic liver diseases in Japan," J. Gastroenterol. And Hepatology 7:30-35 (1992)	
	42.	STOLZ, Donna Beer and MICHALOPOULOS, Michael, "Differential Modulation of Hepatocyte Growth Factor-Stimulated Motility by Transforming Growth Factor β 1 on	

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	7	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
		Rat Liver Epithelial Cells In Vitro," J Cell. Physiol. 175:30-40 (1998)		
	43.	SUZUI, Masumi et al., "Growth Inhibition of Human Hepatoma Cells by Acyclic Retinoid Is Associated with Induction of p21 ^{CIP1} and Inhibition of Expression of Cyclin D1 ¹ ," Cancer Res. 62:3997-4006 (2002)		
	44.	THATTE, Urmila et al., "Modulation of programmed cell death by medicinal plants," Cellular and Molecular Biol. 46(1):199-214 (2000)		
	45.	TREIBER, G., "Systemic Treatment of Hepatocellular Carcinoma," Dig. Dis. 19:311-323 (2001)		
	46.	WANG, D.L. et al., "Analysis of 70 Cases of Primary Liver Carcinoma Treated by Pu Tuo Plaster and Herbs" Zhong Xi Yi Jie He Za Zhi 10(12):723-725 (1990) Abstract		√
	47.	WU, Lii-Tzu and CHUNG, Jing-Gung, "Effects of Vitamin C on Arylamine N-Acetyltransferase Activity in Human Liver Tumor Cells," Anticancer Res. 18:3481-3486 (1998)		
	48.	ZHANG, Yuesheng et al., "A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure," PNAS USA 89:2399-2403 (1992)		
	49.	ZHENG, Q.S. and ZHENG, R.L., "Effects of ascorbic acid and sodium selenite on growth and redifferentiation in human hepatoma cells and its mechanisms," Pharmazie		

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,558
				Filing Date	December 12, 2005
				First Named Inventor	Can V. BUI
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	8	Of	8	Attorney Docket Number	30915-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		57(4): 265- 269 (2002)	

Examiner Signature	/Susan Hoffman/	Date Considered	06/07/2010
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.